Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab)
Amneal Pharmaceuticals, Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR





















